Nasdaq · Healthcare
Alkermes plc. (ALKS)
As-reported financials and recent SEC filings for Alkermes plc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.48B
Net income
$241.7M
Net margin
16.4%
Diluted EPS
$1.43
ROE
13.3%
P/E (TTM)
61.2×
Market cap
$9.18B
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.48B | $1.56B | $1.66B | $1.11B | $1.17B |
| Gross profit | $1.28B | $1.31B | $1.41B | $893.7M | $976.4M |
| Operating income | $254.0M | $420.6M | $414.1M | $-6.1M | $97.7M |
| Net income | $241.7M | $367.1M | $355.8M | $-158.3M | $-48.2M |
| Diluted EPS | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.29 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-15
View on EDGAR →1442026-06-12
View on EDGAR →42026-06-12
View on EDGAR →1442026-06-04
View on EDGAR →42026-06-04
View on EDGAR →1442026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-05-29
View on EDGAR →Go deeper on ALKS
Search Alkermes plc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.